Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. | MicrobiomeTrials← Back to trialsNCT07730151
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-01Est. Completion: 2031-12-31
Enrollment target: 200 participants Other microbiome trials you might be interested in
Prostate CancerPesticide ExposuresLymphomaMultiple Myeloma
The "Agricultural Health Study" (AHS) is a collaborative effort between the National Cancer Institute and the National I…
Research Triangle Park, United States
AdenocarcinomaProstate CancerNeoplasmsCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type
Background:
Prostate cancer is the second most common cause of cancer-related death among men in the United States. Ear…
Bethesda, United StatesEst. completion Jun 15, 2027